CM
CORT icon

Castleark Management’s Corcept Therapeutics CORT Stock Holding History

Castleark Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,740
Closed -$228K – 303
2025
Q3 		$228K Sell
2,740
-34,200
-93% -$2.47M 0.01% 260
2025
Q2 		$2.71M Buy
+36,940
New +$2.68M 0.08% 170
2017
Q4 		– Sell
-182,252
Closed -$3.52M – 409
2017
Q3 		$3.52M Buy
+182,252
New +$2.72M 0.11% 217

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Castleark Management's CORT Position: Q4 2025 in Review

Castleark Management sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 2,740 shares — an estimated $228K sold.

Castleark Management first reported a position in CORT in Q3 2017 and held it in 3 quarters. The position peaked at $3.52M in Q3 2017. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • Castleark Management reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Castleark Management sold 2,740 Corcept Therapeutics shares in Q4 2025, an estimated $228K.
  • Castleark Management first reported a position in Corcept Therapeutics in Q3 2017 and held it in 3 quarters.
  • Castleark Management's Corcept Therapeutics position peaked at $3.52M in Q3 2017.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Castleark Management's 13F filing for Q4 2025, filed 13 Feb 2026.